These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 6686919)
1. [Use of a thromboxane synthetase inhibitor for the protection of platelet number and function during extracorporeal circulation. Experimental study]. Massonnet Castel S; Pelissier E; Fabiani JN; Terrier E Agressologie; 1983 Dec; 24(12):605-8. PubMed ID: 6686919 [No Abstract] [Full Text] [Related]
2. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism. Dale J; Thaulow E; Myhre E; Parry J Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091 [TBL] [Abstract][Full Text] [Related]
3. Amelioration of the deleterious effects of platelets activated during cardiopulmonary bypass. Comparison of a thromboxane synthetase inhibitor and a prostacyclin analogue. Huddleston CB; Hammon JW; Wareing TH; Lupinetti FM; Clanton JA; Collins JC; Bender HW J Thorac Cardiovasc Surg; 1985 Feb; 89(2):190-5. PubMed ID: 2578591 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of thromboxane synthesis and platelet aggregation by pyridine and its derivatives. Tai HH; Lee N; Tai CL Adv Prostaglandin Thromboxane Res; 1980; 6():447-52. PubMed ID: 7189951 [TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of thromboxane synthetase with dazoxiben - basis of its inhibitory effect on platelet adhesion. Menys VC; Davies JA Thromb Haemost; 1983 Apr; 49(2):96-101. PubMed ID: 6346575 [TBL] [Abstract][Full Text] [Related]
8. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis. Aiken JW; Shebuski RJ; Miller OV; Gorman RR J Pharmacol Exp Ther; 1981 Nov; 219(2):299-308. PubMed ID: 6270303 [No Abstract] [Full Text] [Related]
10. [Evaluation of prostaglandin I2 and its derivative in extracorporeal circulation]. Takeda H; Matsukura H; Kawakami T; Tanabe T Kyobu Geka; 1983 Jun; 36(6):479-84. PubMed ID: 6355587 [No Abstract] [Full Text] [Related]
11. Evaluation of a thromboxane synthetase inhibitor in circumflex coronary artery occlusion and reperfusion. Huddleston CB; Lupinetti FM; Clanton J; Collins J; Oates JA; Hammon JW Curr Surg; 1983; 40(3):211-5. PubMed ID: 6683615 [No Abstract] [Full Text] [Related]
12. [Experimental studies of the preservation platelet during extracorporeal circulation]. Matsukura H; Uzawa S; Goda T; Takeda H; Sakai K; Kawakami T; Tanabe T Kyobu Geka; 1983 Dec; 36(11):890-2. PubMed ID: 6656030 [No Abstract] [Full Text] [Related]
13. Thromboxane synthetase inhibition results in increased platelet sensitivity to prostacyclin. Bertelé V; Falanga A; Roncaglioni MC; Cerletti C; de Gaetano G Thromb Haemost; 1982 Jun; 47(3):294. PubMed ID: 7051411 [No Abstract] [Full Text] [Related]
14. Platelet thromboxane synthetase inhibitors with low doses of aspirin: possible resolution of the "aspirin dilemma". Bertelé V; Falanga A; Tomasiak M; Dejana E; Cerletti C; de Gaetano G Science; 1983 Apr; 220(4596):517-9. PubMed ID: 6682245 [TBL] [Abstract][Full Text] [Related]
15. Clinical prospects for a thromboxane synthetase inhibitor. A Pfizer Central Research Symposium--26th-27th March, 1982. Br J Clin Pharmacol; 1983; 15 Suppl 1():5S-139S. PubMed ID: 6681704 [No Abstract] [Full Text] [Related]
16. [Experimental study upon platelet preservation by prostaglandin I2 during extracorporeal circulation]. Osada H; Kawada T; Hoson M; Funaki S; Arase K; Masaki H; Taira Y; Kuwahara M; Noguchi T Nihon Kyobu Geka Gakkai Zasshi; 1984 Oct; 32(10):1795-803. PubMed ID: 6394659 [No Abstract] [Full Text] [Related]
17. Effect of SQ 80,338 (1-(3-phenyl-2-propenyl)-1H-imidazole) on thromboxane synthetase activity and arachidonic acid-induced platelet aggregation and bronchoconstriction. Harris DN; Greenberg R; Phillips MB; Osman GH; Antonaccio MJ Adv Prostaglandin Thromboxane Res; 1980; 6():437-41. PubMed ID: 7189949 [No Abstract] [Full Text] [Related]
18. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation. Straub A; Wendel HP; Dietz K; Schiebold D; Peter K; Schoenwaelder SM; Ziemer G Thromb Haemost; 2008 Mar; 99(3):609-15. PubMed ID: 18327411 [TBL] [Abstract][Full Text] [Related]
19. Selective thromboxane synthetase inhibitor and ischemic heart disease. Ito T; Ogawa K; Watanabe J; Chen LS; Shikano M; Imaizumi M; Shibata T; Ito Y; Miyazaki Y; Satake T Biomed Biochim Acta; 1984; 43(8-9):S125-32. PubMed ID: 6542777 [No Abstract] [Full Text] [Related]
20. Inhibition of arachidonate-induced human platelet aggregation by a single low oral dose of aspirin in combination with a thromboxane synthase inhibitor. Cerletti C; Rajtar G; Bertelé V; de Gaetano G Thromb Haemost; 1984 Oct; 52(2):215. PubMed ID: 6441306 [No Abstract] [Full Text] [Related] [Next] [New Search]